CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Canopy Growth Corp (CGC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Canopy Growth Corp (CGC)

Medicinal Chemicals & Botanical Products · market cap $378M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Canopy Growth Corporation (CGC) is a Canadian cannabis company with a market cap of ~$359M and ~1,029 employees, a shadow of its 2019 peak when it was the world's largest cannabis company by market cap. The company has pivoted toward a pharmaceutical pipeline anchored by CHI-554 (Phase 2, Anxiety) and a cannabidiol program (Phase 2, Menstrual Discomfort), while revenues have collapsed from $607M in FY2021 to $314M in FY2025 and cumulative net losses since 2021 exceed $6.5B.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
CHI-554Phase 2Anxiety
CannabidiolPhase 2Menstrual Discomfort
Price & technical context
3-month
-2.0%
6-month
-13.0%
12-month
-36.3%
52-wk range
$0.86–$1.92
vs 50-day MA
-7.9%
vs 200-day MA
-16.4%
Realized vol
97.1%
Max drawdown
-92.5%

Daily closes through 2026-06-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for CGC (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.